ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 934,33
-0,63%
Dow Jones
37 903,29
0,00%
DAX
17 963,63
0,23%
Brent Oil
83,755
0,26%
Bitcoin
58 765,03
0,91%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) Actualités

NRSN NeuroSense Therapeutics Ltd

1,26
0,00 (0,00%)
Avant marché
Dernière mise à jour : 14:24:06
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
NeuroSense Therapeutics Ltd NRSN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,26 14:24:06
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,26
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
22/4/202414:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
18/4/202414:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
12/4/202414:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
11/4/202401:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
09/4/202414:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
05/4/202415:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
22/2/202414:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202414:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
13/2/202419:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202416:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202415:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202415:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
09/1/202414:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202414:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202414:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
27/12/202323:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/12/202323:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/12/202323:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
21/12/202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202322:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/12/202315:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202315:24PRNUSNeuroSense Reports New Data: Statistically Significant..
05/12/202321:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/12/202321:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/12/202314:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202314:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
05/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
04/12/202322:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
04/12/202312:17EDGAR2Form POS AM - Post-Effective amendments for registration..
28/11/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202314:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
21/11/202316:36EDGAR2Form POS AM - Post-Effective amendments for registration..
13/11/202315:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202315:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
09/11/202315:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
06/11/202314:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202314:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
01/11/202314:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
17/10/202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/10/202314:30PRNUSNeuroSense CEO Provides Q3 2023 Update
04/10/202315:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202315:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
02/10/202317:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202315:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202315:05PRNUSEuropean Medicines Agency Grants NeuroSense SME Status
19/9/202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/9/202315:00PRNUSNeuroSense Granted Patents in Europe, Japan, and Israel for..
14/9/202315:00PRNUSNeuroSense to Participate in Upcoming ALS Conferences:..
12/9/202315:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/9/202322:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]

Dernières Valeurs Consultées

NASDAQ
NRSN
NeuroSense Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés